Oss, Netherlands
Summary
This organization specializes in developing novel therapies for cancer, particularly focusing on hematological malignancies. They utilize covalent binding technology to create highly selective treatments that aim to directly kill cancer cells or enhance the immune system's ability to recognize and eliminate cancer. The company is committed to addressing significant unmet medical needs in blood cancers and is advancing a pipeline of first-in-class and best-in-class agents.
Based on content on acerta-pharma.com
hartwigmedicalfoundation.nl
Amsterdam, Netherlands
Healthcare and Medical Research
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
11.7 years — Since May 2013
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Pharmaceuticals and Biotechnology
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Microsoft
TXT Record
DocuSign
TXT Record
Mimecast
TXT Record
Workplace
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|